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Abstract Premenstrual exacerbation (PME) of asthma occurs during the 5^10 days leadingupto themenses and can
be demonstratedin about 40% of asthmatic females.Peakexpiratory £owrate (PEFR) and b2-agonistconsumptionwere
recorded during threemenstrual cycles in 67 femaleswithmild^severe asthma. Allwere treatedwith inhaled glucocor-
ticosteroids (IGC) and b2-agonists, as required. Following, the patients with a premenstrual reduction in PEFR420%,
received either salmeterol, 50 mg62 day71or placebo, inthe10 daysleadinguptothemenses, in a randomized, double-
blind, cross-overdesign.Thirteenpatients (19?4%) showed PME (mean+SEMdecrease in PEFR 27+2?2%) in association
with a signi¢cant increase in themean daily b2-agonist consumption.Following administration of salmeterol, therewas a
complete ablation of the PME in seven patients, a partial ablation in two patients and no e¡ect in the remaining four
patients.Only one patient showed a partial ablation of the PME following placebo.Therewas also a signi¢cantdecrease
inthe b2-agonists consumptionintheresponders.About 20% ofthewomenwith asthma, underchronic IGCtreatment,
had PMEof asthma.In 54% ofthem, itcouldbepreventedby theuse of long-actingbronchodilators (LABD) during the10
days leadingupto themenses, andpartiallyprevented in another15%.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1132, available online at http://www.idealibrary.comon
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Premenstrual exacerbation (PME) of asthma was recog-
nized several decades ago (1^3) but little attention has
been paid to the problem.Usually, theworsening in asth-
ma symptoms occurs in the 5^10 days leading up to the
menses and can be demonstrated in about 40% of asth-
matics (1,4).The large variability in the prevalence of oc-
currence depends mainly on the de¢nition of PME,
whether the exacerbation is only reported by the pa-
tient or is objectivelymeasured andwhether the asthma
symptoms arewell controlledwith chronic medication.
Themechanismofpremenstrual deterioration of asth-
ma is poorlyunderstood although it is likely to berelated
to the £uctuations in the absolute concentrations of es-
trogen or progesterone (4,5). In fact, oestrogen (4), pro-
gesterone (5) or GnRH analogues (6) administration
resulted in elimination of the premenstrual dips in peak
expiratory £ow rate (PEFR). However, the need for par-
enteral administration, the prolonged periods of ame-
norrhoea following discontinuation of the drug and theReceived14 February 2001and accepted in revised form14 May 2001.
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attractivity of such treatments.
In the present study the prevalence of PME of asthma
was assessed in a group of young asthmatic women,
whose symptoms of asthma were controlled with in-
haled gluco corticosteroids (IGC). In the second stage of
the study the e¡ect of long-acting bronchodilators
(LABD) on PME of asthmawas also evaluated.
PATIENTSANDMETHODS
Sixty-seven female patients, aged 18^45 years, with
mild to severe asthma, referred to our outpatient
clinic, were recruited for the study. All satis¢ed the
American Thoracic Society de¢nition of asthma, with
symptoms of episodic wheezing, cough and shortness
of breath responding to bronchodilators, and reversi-
ble air£ow obstruction documented in at least one
previouspulmonary function study (7). All subjectswere
treatedby their primaryphysicianwith inhaled corticos-
teroids (budesonide 400^800mgday71 or £uticasone
dipropionate 200^500mgday71) and b2-agonists, as
required, only. Although some patients probably
needed higher doses of steroids, no patient has re-
ceived doses higher than 800mgday71 budesonide,
or 500mgday71 £uticasone dipropionate, from their
primary phisician.
LABDINPMEOFASTHMA 741Study design
The study design is shown in Fig.1.During the ¢rst phase
of the study all patients were studied during threemen-
strual cycles andwere required to be compliantwith the
recording of prebronchodilator morning and evening
PEFR and b2-agonist consumption in a diary card.The in-
formation on the diary cardwas veri¢edby a respiratory
therapist, daily by phone, and onceweekly by a personal
visit.
After three menstrual cycles the subjects were sepa-
rated into two groups: thosewith a premenstrual reduc-
tion in PEFR420%, in at least 3 days during the 10 days
leading up to the menses, who proceeded to the next
phase of the study, and thosewithout a premenstrual re-
duction in PEFRwhowere excluded from the next phase
of the study.
The patients with a premenstrual reduction in
PEFR420%, in at least 3 days during the 10 days leading
up to the menses, constituted the study group and were
followed for four menstrual cycles during which they re-
ceived either LABD (salmeterol, 50mg62day71, via Dis-
khaler) or placebo, in the 7^10 days leading up to the
menses, in a randomized, double-blind, cross-overdesign.FIG. 1. The study design. In the ¢rst phase of the study all patient
premenstrualreductionin PEFR420%were followed for fourmen
7^10 days leadingupto themenses, in a randomized, double-blind,
TABLE 1. Peak £owmeasurements in13 womenwith PMEof as
Week Me
With PME
Morning Even
Premenstrual 228 (32) 241 (
Mid-cycle 290 (34) 303 (Prebronchodilator morning and evening PEFR, and
b2-agonist consumption were again recorded in diary
cards during the last fourmenstrual cycles.
RESULTS
Sixty-seven patients were recruited for the study.
Twenty-three (34%) had mild asthma (mid-cycle
FEV1480% of predicted normal values), 35 (52%) had
moderate asthma (mid-cycle FEV1580% and 460% of
predicted normal values) and nine (14%) had severe dis-
ease (FEV1560% of predicted normal values) (GINA,
1995).
Thirteen patients (19?4%) showed a signi¢cant decrease
(420%) in PEFR during the premenstrual week com-
pared to the mid-cycle values (Table 1) and were
recruited for the next stage of the study.Themean+SEM
decrease in PEFR in this group was 27+2?2%, P50?01,
while the mean decrease was 4+0?3% in the remaining
patients.
There was no statistically signi¢cant di¡erence be-
tween patients ‘with PME’or ‘without PME’of asthma in
the PEFR or in the mean daily b2-agonist (2?7+0?4 ands were studied during three menstrual cycles.The patients with a
strualcyclesinwhichtheyreceivedeither LABDorplacebo, inthe
cross-overdesign.
thma and in 54 womenwithout PME
an (+SEM) peak £ow (1min71)
No PME
ing Morning Evening
35) 315 (41) 331 (44)
37) 327 (40) 341 (45)
742 RESPIRATORYMEDICINE2?4+0?3 pu¡sday71, respectively), during themid-cycle
period. However, during the 10 days leading up to the
menses therewas a signi¢cant increase in themean daily
b2-agonist consumption in the PME group (7?6+1?4
pu¡sday71,P50?001), butnot in the‘without PME’group
(2?9+0?4 pu¡s day71).
Following therapy with LABD, in the13 patients with
PME of asthma, there was a complete ablation of the
PME (decrease in PEFR510%) in seven patients, a partial
ablation (decrease in PEFR410% but520%) in two pa-
tients and no e¡ect in the remaining four patients.Only
one patient showed a partial ablation of the PME follow-
ing placebo.
b2-agonists consumption was almost identical in the
three subgroups before treatment. Following placebo
there was a small but insigni¢cant decrease in the mean
b2-agonists consumption during the10 days leading up to
the menses in all three subgroups of patients. However,
during LABD treatment therewas a signi¢cant decrease
in the b2-agonists consumption (from 7?2+1?3 pu¡s -
day71 to 1?7+0?3 pu¡sday71, P50?05), in the ‘complete
ablation subgroup’, a small but not signi¢cant decrease in
the ‘partial ablation subgroup’, and an insigni¢cant de-
crease in the‘no ablation group’ (Fig. 2).
DISCUSSION
In the present study 20% of thewomenwith asthma, un-
der chronic IGC treatment, had objectivemeasurements
of PME of the disease. In 54% of the patients, with PME,
the deterioration couldbepreventedby theuse of LABD
during the10 days leading up to themenses, andpartially
prevented in15%.FIG. 2. b2-agonistconsumptionbeforetreatment, followingplace
inthe‘partial ablation subgroup’, and inthe‘no ablation group’.N.S.,Many femaleswith asthma reportworsening of symp-
toms in the premenstrual period (1) and there is a higher
rate of admissions to hospital during this part of the cy-
cle (3).The frequency with which PME of asthma occurs
is not clear and has been reported to occur in 25^100%
ofpatients (1,4).However,when objectivemeasurements
are performed, such as in the study of Gibbs et al., it is
obvious that in about 40% of women there is a pre-
menstrual decrease in peak £ows, but an appreciable de-
terioration occurs less frequently (1). The regular
treatment of these patients was not mentioned in that
study. Studies of bronchial hyper-responsiveness (BHR)
are also not consistent.While some found no di¡erence
in BHR at two di¡erent times of themenstrual cycle (8),
others found an increase in BHR during the luteal
phase (9).
The mechanism of PME of asthma is poorly under-
stood, but it is likely to be related to £uctuation in the
concentrations of sex hormones during the menstrual
cycle.Therefore, the e¡ect of exogenous sex hormones
in preventing PME of asthmawas studied but the results
were inconsistent; some have shown improvement
(4,10,11), others no e¡ect (12) and some suggested even a
deterioration (13,14). Recently, it was proposed that
GnRH-analogue therapy may prevent PME of asthma
(6).However, bone loss is a potential problemwhenusing
GnRH-analogues (15).
In the present study a marked relationship between
asthma and themenstrual cycle was noted in 20% of the
patients. This rate is somehow lower than in previous
published series.However, all our patients had signi¢cant
asthma and were under regular treatment of IGC. This
treatmentmight prevent the PME in some patients.boandduring LABD treatmentinthe‘complete ablationsubgroup’,
not signi¢cant. *P50?05.
LABDINPMEOFASTHMA 743More thanhalf of the patientswith PME, while on IGC
treatment, were successfully treated with LABD.These
drugs are very e¡ective in controlling asthma symptoms
and they confer bene¢t in patients with chronic asthma
who remain symptomatic despite IGC therapy (16). To
our knowledge there areno otherdata of PME of asthma
being treated with inhaled LABD in the10 days prior to
menses.
In conclusion, if an objective reduction in PEFR420%
prior to the menses is considered as a criteria, the pre-
valence of PME of asthma, in patients under regular
treatment of IGC, is about 20%. The addition of LABD
to the treatment in the days leading to the menses, re-
sulted in complete improvement of symptoms in more
than half of the patients. Thus, conventional treatment
with IGC and LABD results in preventing PME in most
of the patients.
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